Janus Henderson Group PLC Buys Shares of 19,100 Urogen Pharma $URGN

Janus Henderson Group PLC purchased a new stake in Urogen Pharma (NASDAQ:URGN) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 19,100 shares of the company’s stock, valued at approximately $343,000.

Other hedge funds have also recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Urogen Pharma by 27.2% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,275 shares of the company’s stock valued at $53,000 after purchasing an additional 486 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Urogen Pharma by 7.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,320 shares of the company’s stock worth $258,000 after buying an additional 1,653 shares in the last quarter. Main Street Financial Solutions LLC lifted its holdings in Urogen Pharma by 8.2% during the second quarter. Main Street Financial Solutions LLC now owns 25,968 shares of the company’s stock worth $356,000 after buying an additional 1,968 shares during the period. Barclays PLC lifted its holdings in Urogen Pharma by 3.8% during the fourth quarter. Barclays PLC now owns 57,744 shares of the company’s stock worth $1,352,000 after buying an additional 2,125 shares during the period. Finally, Osaic Holdings Inc. boosted its position in Urogen Pharma by 491.2% during the 2nd quarter. Osaic Holdings Inc. now owns 3,695 shares of the company’s stock valued at $50,000 after acquiring an additional 3,070 shares in the last quarter. Hedge funds and other institutional investors own 91.29% of the company’s stock.

Insider Transactions at Urogen Pharma

In other Urogen Pharma news, insider Mark Schoenberg sold 10,000 shares of Urogen Pharma stock in a transaction dated Thursday, July 9th. The stock was sold at an average price of $40.00, for a total transaction of $400,000.00. Following the completion of the sale, the insider owned 119,763 shares of the company’s stock, valued at approximately $4,790,520. The trade was a 7.71% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 25,222 shares of company stock valued at $892,661. Company insiders own 4.80% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently issued reports on URGN shares. Guggenheim lifted their price target on Urogen Pharma from $42.00 to $58.00 and gave the company a “buy” rating in a report on Thursday. TD Cowen upped their price objective on Urogen Pharma from $50.00 to $60.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Jefferies Financial Group raised Urogen Pharma to a “strong-buy” rating in a research report on Friday, April 24th. HC Wainwright boosted their target price on shares of Urogen Pharma from $45.00 to $75.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Urogen Pharma in a research report on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $48.78.

Urogen Pharma Stock Performance

Shares of URGN stock opened at $46.31 on Tuesday. The stock’s 50-day simple moving average is $36.83 and its 200-day simple moving average is $27.37. The firm has a market capitalization of $2.26 billion, a price-to-earnings ratio of -23.39 and a beta of 1.57. Urogen Pharma has a fifty-two week low of $15.86 and a fifty-two week high of $48.19.

Urogen Pharma (NASDAQ:URGN) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.02). The business had revenue of $72.46 million for the quarter, compared to analyst estimates of $63.55 million. As a group, equities analysts forecast that Urogen Pharma will post -0.2 earnings per share for the current year.

About Urogen Pharma

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.